IAMA Therapeutics Appoints Torsten M. Madsen as Chief Executive Officer

GENOA, Italy, November 10, 2025 – IAMA Therapeutics, a clinical-stage biopharmaceutical company advancing selective NKCC1 inhibitor therapies for central nervous system (CNS) disorders, today announced the appointment of Torsten M. Madsen, MD, PhD, as Chief Executive Officer (CEO).

Dr. Madsen brings more than 20 years of international experience in neuroscience drug development, clinical strategy, and corporate leadership across the pharmaceutical and biotechnology industries. As CEO, he will lead IAMA’s next phase of growth, focusing on the advancement of its lead candidate IAMA-6, a best-in-class NKCC1 inhibitor, toward Phase 2 clinical development.

Ciro Spedaliere, Chairman of the Board at IAMA Therapeutics, commented: “We are delighted to welcome Torsten as CEO at a pivotal time for IAMA. His extensive expertise in CNS clinical development and his proven ability to drive programs from early research to late-stage trials will be key to accelerating IAMA-6’s path to patients. With Torsten’s leadership, IAMA is poised to strengthen its position as an innovator in neuroscience.”
In response to his appointment, Dr. Torsten M. Madsen added: “I am honored to join IAMA Therapeutics and lead a company with such a strong scientific foundation and promising clinical data. The successful completion of our Phase 1 study marks a major milestone, and I look forward to working with the Board, investors, and the team to advance IAMA-6 through Phase 2 and beyond, bringing transformative therapies to patients with high unmet needs.”

Dr. Madsen is a physician-scientist with a distinguished career spanning more than two decades in CNS drug development and clinical research. He earned his MD and PhD degrees from the University of Copenhagen, followed by clinical training in Internal Medicine and Psychiatry, and postdoctoral research at Yale University School of Medicine and the Instituto Cajal in Madrid.
He has led programs across all phases of drug development—from discovery through clinical proof-of-concept and registration—covering a broad range of CNS disorders including depression, schizophrenia, pain, epilepsy, and neurodegeneration.

Dr. Madsen is a physician-scientist with a distinguished career in CNS drug development. He has held senior leadership positions at H. Lundbeck A/S, Naurex, Aptinyx, and Syndesi Therapeutics, where he guided the development of SV2A modulators for cognitive disorders until the company’s acquisition by AbbVie. Earlier in his career, he contributed to the global approval of the antidepressant vortioxetine and most recently served as CEO of Hoba Therapeutics, leading programs in pain and hearing loss.

About IAMA Therapeutics

IAMA Therapeutics is a clinical-stage biopharmaceutical company committed to developing innovative treatments for central nervous system disorders. The company’s lead compound, IAMA-6, is a selective NKCC1 inhibitor designed to restore chloride homeostasis and rebalance GABAergic signaling in conditions such as autism, epilepsy, and other neurodevelopmental disorders.

For more information, please visit https://iamatherapeutics.com/

Contact
media@iamatherapeutics.com